Jim Simons Biotechnology

Renaissance Technologies LLC

$63.4 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
UTHR United Therapeutics Corp	$14.2B	$737 Million 1.16% of portfolio	2,089,392	Q4 2024 Reduced 3.06%
NVO Novo Nordisk A S	$173B	$715 Million 1.13% of portfolio	8,312,996	Q4 2024 Added 1.51%
VRTX Vertex Pharmaceuticals Inc	$129B	$563 Million 0.89% of portfolio	1,397,209	Q4 2024 Reduced 14.36%
EXEL Exelixis, Inc.	$11.9B	$509 Million 0.8% of portfolio	15,295,865	Q4 2024 Reduced 0.42%
CORT Corcept Therapeutics Inc	$6.28B	$312 Million 0.49% of portfolio	6,198,602	Q4 2024 Reduced 4.77%
INCY Incyte Corp	$13.8B	$282 Million 0.45% of portfolio	4,085,932	Q4 2024 Reduced 9.19%
REGN Regeneron Pharmaceuticals, Inc.	$70.6B	$176 Million 0.28% of portfolio	247,743	Q4 2024 Added 17.18%
JAZZ Jazz Pharmaceuticals PLC	$8.7B	$123 Million 0.19% of portfolio	1,001,874	Q4 2024 Reduced 4.58%
INVA Innoviva, Inc.	$1.2B	$73.9 Million 0.12% of portfolio	4,261,732	Q4 2024 Reduced 1.57%
ADMA Adma Biologics, Inc.	$3.89B	$64.7 Million 0.1% of portfolio	3,769,888	Q4 2024 Added 2.8%
CPRX Catalyst Pharmaceuticals, Inc.	$2.49B	$56.5 Million 0.09% of portfolio	2,706,116	Q4 2024 Added 7.13%
MDGL Madrigal Pharmaceuticals, Inc.	$5.84B	$49.6 Million 0.08% of portfolio	160,782	Q4 2024 Added 261.33%
MRNA Moderna, Inc.	$12.8B	$42 Million 0.07% of portfolio	1,010,758	Q4 2024 Added 225.74%
TVTX Travere Therapeutics, Inc.	$1.32B	$42 Million 0.07% of portfolio	2,409,514	Q4 2024 Added 28.51%
GMAB Genmab A/S	$13B	$40.2 Million 0.06% of portfolio	1,926,150	Q4 2024 Added 7.82%
LEGN Legend Biotech Corp	$6.19B	$29.5 Million 0.05% of portfolio	908,100	Q4 2024 Added 4,917.13%
PTCT Ptc Therapeutics, Inc.	$4.09B	$29.5 Million 0.05% of portfolio	653,100	Q4 2024 Added 21.35%
BMRN Biomarin Pharmaceutical Inc	$13.2B	$28.6 Million 0.05% of portfolio	435,871	Q4 2024 Added 4.06%
VCYT Veracyte, Inc.	$2.28B	$23.8 Million 0.04% of portfolio	600,700	Q4 2024 Added 1.08%
ACAD Acadia Pharmaceuticals Inc	$2.72B	$22.5 Million 0.04% of portfolio	1,226,533	Q4 2024 Added 204.2%
MRVI Maravai Lifesciences Holdings, Inc.	$299M	$21.6 Million 0.03% of portfolio	3,972,189	Q4 2024 Reduced 4.02%
FOLD Amicus Therapeutics, Inc.	$2.53B	$19.9 Million 0.03% of portfolio	2,108,616	Q4 2024 Added 174.1%
HRMY Harmony Biosciences Holdings, Inc.	$2.09B	$19.6 Million 0.03% of portfolio	568,671	Q4 2024 Added 15.44%
VNDA Vanda Pharmaceuticals Inc.	$270M	$18.5 Million 0.03% of portfolio	3,853,799	Q4 2024 Reduced 3.93%
MDXG Mimedx Group, Inc.	$902M	$17.4 Million 0.03% of portfolio	1,804,557	Q4 2024 Added 18.39%
NVAX Novavax Inc	$594M	$11.3 Million 0.02% of portfolio	1,407,530	Q4 2024 Reduced 31.83%
BPMC Blueprint Medicines Corp	$5.3B	$11 Million 0.02% of portfolio	126,300	Q4 2024 Reduced 27.62%
RARE Ultragenyx Pharmaceutical Inc.	$2.74B	$10.7 Million 0.02% of portfolio	254,700	Q4 2024 Added 39.87%
VIR Vir Biotechnology, Inc.	$919M	$9.08 Million 0.01% of portfolio	1,237,600	Q4 2024 Added 4.68%
CYTK Cytokinetics Inc	$4.28B	$9.04 Million 0.01% of portfolio	192,167	Q4 2024 Reduced 21.36%
SNDX Syndax Pharmaceuticals Inc	$776M	$9 Million 0.01% of portfolio	680,965	Q4 2024 New
APLS Apellis Pharmaceuticals, Inc.	$2.65B	$8.68 Million 0.01% of portfolio	271,913	Q4 2024 Reduced 26.97%
PTGX Protagonist Therapeutics, Inc	$2.58B	$8.54 Million 0.01% of portfolio	221,167	Q4 2024 Added 53.41%
GLPG Galapagos Nv	$1.7B	$8.14 Million 0.01% of portfolio	296,100	Q4 2024 Added 1.52%
IDYA Ideaya Biosciences, Inc.	$884M	$7.31 Million 0.01% of portfolio	284,267	Q4 2024 Added 66.86%
ABCL Ab Cellera Biologics Inc.	$696M	$7.29 Million 0.01% of portfolio	2,486,893	Q4 2024 Reduced 15.6%
IONS Ionis Pharmaceuticals Inc	$4.67B	$7.18 Million 0.01% of portfolio	205,514	Q4 2024 Added 7.87%
VRDN Viridian Therapeutics, Inc.\De	$609M	$7.12 Million 0.01% of portfolio	371,200	Q4 2024 Added 522.82%
XERS Xeris Biopharma Holdings, Inc.	$790M	$7.12 Million 0.01% of portfolio	2,098,840	Q4 2024 Added 31.28%
AKBA Akebia Therapeutics, Inc.	$392M	$7.11 Million 0.01% of portfolio	3,823,527	Q4 2024 Added 2.84%
ITOS I Teos Therapeutics, Inc.	$245M	$6.43 Million 0.01% of portfolio	837,200	Q4 2024 Added 56.08%
RLAY Relay Therapeutics, Inc.	$368M	$6.38 Million 0.01% of portfolio	1,549,190	Q4 2024 Added 130.85%
MNKD Mannkind Corp	$1.34B	$6.31 Million 0.01% of portfolio	981,645	Q4 2024 Added 50.66%
AUPH Aurinia Pharmaceuticals Inc.	$1.2B	$6.29 Million 0.01% of portfolio	700,900	Q4 2024 Added 44.01%
RNA Avidity Biosciences, Inc.	$1.61B	$6.14 Million 0.01% of portfolio	211,200	Q4 2024 Added 48.84%
PBYI Puma Biotechnology, Inc.	$160M	$5.35 Million 0.01% of portfolio	1,755,513	Q4 2024 Reduced 0.95%
KURA Kura Oncology, Inc.	$524M	$5.21 Million 0.01% of portfolio	597,810	Q4 2024 Added 463.39%
GERN Geron Corp	$688M	$5.14 Million 0.01% of portfolio	1,452,700	Q4 2024 New
ZLAB Zai Lab LTD	$3.44B	$4.92 Million 0.01% of portfolio	187,800	Q4 2024 Added 112.68%
VCEL Vericel Corp	$2.18B	$4.91 Million 0.01% of portfolio	89,500	Q4 2024 Added 11.46%

Shares Options

Jim Simons

Jim Simons is the founder and chairman of Renaissance Technologies, a successful investment firm that uses quantitative approaches to investing. Simons is known for his expertise in mathematical modeling and has a reputation for being a skilled and successful investor. He has generated strong returns for his clients over the long term.

Track Jim Simons's portfolio

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account